Clinical Trial Update: Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

A Phase 2 trial of irinotecan in patients with advanced neuroendocrine tumors, including carcinoma of unknown primary and neuroendocrine carcinoma of the skin, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma of Unknown Primary
• Neuroendocrine Carcinoma
• Neuroendocrine Carcinoma of the Skin

Drugs mentioned

• Irinotecan (Camptosar) (Irinotecan)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Carcinoma of Unknown Primary, Neuroendocrine Carcinoma | Phase 2 | Status: COMPLETED